Article Text
PDF
Statistics from Altmetric.com
Q In patients with type 2 diabetes mellitus, is atorvastatin better than placebo for primary prevention of major cardiovascular disease (CVD) events?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Endocrine ★★★★★★☆ Cardiology ★★★★★★☆
METHODS
Design:
randomised placebo controlled trial (Collaborative Atorvastatin Diabetes Study [CARDS]).
Allocation:
concealed.*
Blinding:
blinded (clinicians, patients, pharmacists, data collectors, outcome assessors, monitoring committee, and data analysts).*
Follow-up period:
median 3.9 years.
Setting:
132 clinical centres in the UK and Ireland.
Patients:
2838 patients 40–75 years of age (mean age 62 y, 68% men) with type 2 diabetes mellitus (met 1985 World Health Organization criteria) who had ⩾1 of the following: a history of hypertension, retinopathy, microalbuminuria or macroalbuminuria, or a current smoking habit. Exclusion …
Linked Articles
- Glossary